Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 4/20 | 0.67 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.67 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.67 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2541029 | 0.95 | ADORA1 (0.59) | ADORA1ADORA2AADORA2BGLAADORA3 | |
| SCHEMBL2539378 | 0.93 | ADORA1 (0.56) | ADORA1ADORA2AADORA2BGLAADORA3 | |
| SCHEMBL2538825 | 0.90 | ADORA1 (0.53) | ADORA1ADORA2AADORA2BGLAADORA3 | |
| SCHEMBL2545534 | 0.89 | ADORA1 (0.53) | ADORA1ADORA2AADORA2BGLAADORA3 | |
| SCHEMBL8180993 | 0.89 | ADORA1 (0.53) | ADORA1ADORA2AADORA2BGLAADORA3 | |
| SCHEMBL2537627 | 0.89 | ADORA1 (0.57) | ADORA1ADORA2AADORA2BGLAMAOB | |
| SCHEMBL2537886 | 0.88 | ADORA2A (0.53) | ADORA1ADORA2AADORA2BGLA | |
| SCHEMBL4636332 | 0.88 | ADORA1 (0.53) | ADORA1ADORA2AADORA2BGLAADORA3 | |
| SCHEMBL4636327 | 0.88 | ADORA1 (0.53) | ADORA1ADORA2AADORA2BGLAADORA3 | |
| SCHEMBL4635999 | 0.88 | ADORA1 (0.55) | ADORA1ADORA2AADORA2BGLAADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097415-B1 | 8-ETHINYLXANTHINE DERIVATIVES AS SELECTIVE A2A RECEPTOR ANTAGONISTS | UNIV BONN (DE) | 2014-10-29 | — | — | EP | claimed |
| US-20080221134-A1 | 8-ALKYNYLXANTHINES AND DERIVATIVES | RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAET BONN (DE) | 2008-09-11 | — | — | US | claimed |
| EP-2097415-B1 | 8-ETHINYLXANTHINE DERIVATIVES AS SELECTIVE A2A RECEPTOR ANTAGONISTS | UNIV BONN (DE) | 2014-10-29 | — | — | EP | disclosed |
| US-8044061-B2 | Parkinson's disease, catalepsy, dystonia, dyskinetic syndrome, restless legs syndrome, migraine, pain, dementia, neurodegenerative disorders, alcohol withdrawal and/or ischemic conditions such as e.g. stroke or cardiac ischemia. | UCB PHARMA GMBH (DE) | 2011-10-25 | — | — | US | disclosed |
| US-8044061-B2 | Parkinson's disease, catalepsy, dystonia, dyskinetic syndrome, restless legs syndrome, migraine, pain, dementia, neurodegenerative disorders, alcohol withdrawal and/or ischemic conditions such as e.g. stroke or cardiac ischemia. | UCB PHARMA GMBH (DE) | 2011-10-25 | — | — | US | disclosed |
| US-20080221134-A1 | 8-ALKYNYLXANTHINES AND DERIVATIVES | RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAET BONN (DE) | 2008-09-11 | — | — | US | disclosed |
| US-20080221134-A1 | 8-ALKYNYLXANTHINES AND DERIVATIVES | RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAET BONN (DE) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221134-A1 | 8-ALKYNYLXANTHINES AND DERIVATIVES | SLC6A3, PARK7, SLC18A2 | ADORA1 314/4885ADORA2A 115/4885ADORA2B 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.